Screener
Assembly Biosciences ASMB Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Assembly Biosciences in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Assembly Biosciences’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211987
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| (Unaudited) | ||
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | $31,120 | $58,450 |
| Marketable securities | 195,481 | 189,656 |
| Accounts receivable from collaboration with a related party | 451 | 974 |
| Prepaid expenses and other current assets | 5,561 | 5,469 |
| Total current assets | 232,613 | 254,549 |
Item 1. Financial Statements
FAQ
- What is Assembly Biosciences's cash & equivalents?
- Assembly Biosciences (ASMB) reported cash & equivalents of $31.12M in Q1 2026.
- How has Assembly Biosciences's cash & equivalents changed year-over-year?
- Assembly Biosciences's cash & equivalents increased by 32.9% year-over-year, from $23.41M to $31.12M.
- What is the long-term trend for Assembly Biosciences's cash & equivalents?
- Over 5 years (2020 to 2025), Assembly Biosciences's cash & equivalents has grown at a -0.3% compound annual growth rate (CAGR), from $59.44M to $58.45M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Assembly Biosciences's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude